Clinical trials: Diabete Type 2
Type 2 Diabetes
A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED)
A single dose, open label study to characterize the routes of elimination and determine the mass balance of MK-0941. A single 40 mg dose of MK-0941 will be given orally to male participants with type 2 diabetes.
- Trial name
- NCT00912002
- Testing
- MK-0941
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
The purpose of this study is to investigate the effect of bexagliflozin compared to sitagliptin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03115112
- Testing
- Bexagliflozin, Sitagliptin
- Where
- 56 sites in United States, Czechia and 4 more
- Volunteers
- 386 people
- Sponsor
- Theracos
Diabetes Mellitus Type 2, Hypertension
MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics)
The purpose of this study is to determine whether MC-1 alone and in combination with an ACE inhibitor is effective in reducing blood pressure and metabolic dysfunctions associated with diabetes
- Conditions
- Diabetes Mellitus Type 2, Hypertension, Metabolic Syndrome
- Trial name
- NCT00157729
- Testing
- pyridoxal-5'-phosphate with and without ACE inhibitor
- Where
- Canada
- Volunteers
- 160 people
- Sponsor
- Medicure
Diabetes, Diabetes Mellitus, Type 1
NovoLet® Surveillance Study on Using Human Insulin System in Indonesia
This study is conducted in Asia. The aim of this study is to investigate the safety and efficacy of NovoLet® human insulin delivery system in an outpatient setting.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01492153
- Testing
- biphasic human insulin, isophane human insulin, human soluble insulin
- Where
- Indonesia
- Volunteers
- 1,981 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study in Patients With Type 2 Diabetes
The study is designed to see if once daily oral dosing of LY2608204 will help control diabetes as measured by the glycosylated fraction of hemoglobin A (HbA1c) level.
- Trial name
- NCT01408095
- Testing
- LY2608204, Glimepiride
- Where
- 38 sites in United States, Austria and 5 more
- Volunteers
- 240 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Overweight
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes.
- Conditions
- Diabetes Mellitus, Overweight, Obesity
- Trial name
- AMAZE 2 (NCT07533175)
- Testing
- NNC0487-0111
- Where
- 74 sites in United States, Argentina and 8 more
- Volunteers
- 630 people
- Sponsor
- Novo Nordisk A/S
Adrenocortical Carcinoma
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
This study will investigate the safety and efficacy of Relacorilant in combination with Pembrolizumab for Patients with Adrenocortical Carcinoma which Produces Too Much Stress Hormone (Cortisol).
- Trial name
- NCT04373265
- Testing
- Relacorilant, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Corcept Therapeutics
Atherosclerotic Cardiovascular Disease, Type 2 Diabetes
High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes
To assess the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe compared to high-intensity rosuvastatin in high atherosclerotic cardiovascular disease risk patients with type 2 diabetes
- Trial name
- NCT03403556
- Testing
- Rosuvamibe, Monorova
- Where
- 6 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Yuhan Corporation
Diabetes Mellitus, Type 2
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)
The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT00094757
- Testing
- Comparator: sitagliptin 100 mg, Comparator: sitagliptin 200 mg, Comparator: pioglitazone
- Volunteers
- 521 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Study of Multiple Doses of Saxagliptin (BMS-477118)
To evaluate the positive efficacy trend among doses of saxagliptin (BMS-477118) in subjects with Type 2 diabetes mellitus by assessing the change from baseline in HbA1c following 12 weeks of double-blind treatment.
- Trial name
- NCT00950599
- Testing
- Saxagliptin
- Volunteers
- 423 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Non-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France
The primary objective of this study are: Describe the characteristics of all patients initiating sodium-glucose co-transporter-2 inhibitors (SGLT2i) and the modalities of prescriptions of these two drugs and the concomitant…
- Trial name
- NCT05882071
- Testing
- Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
- Where
- France
- Volunteers
- 547,150 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes
Phase 3 study to examine treatment with ITCA 650 compared to glimepiride when added to metformin monotherapy in reducing HbA1c in patients with type 2 diabetes.
- Trial name
- NCT01455883
- Testing
- ITCA 650 60 mcg/day, glimepiride
- Where
- United States
- Sponsor
- Intarcia Therapeutics
Type 2 Diabetes Mellitus
A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers
A single centre, open, randomized, placebo controlled, 3 period cross-over study to evaluate the effects of single oral doses of pioglitazone 45mg, rosiglitazone 8mg and placebo on urinary sodium excretion in 12 healthy male…
- Trial name
- NCT01088594
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Diabetes Mellitus, Type 2
HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
The purpose of this study is to assess the efficacy of HSK7653 (as monotherapy) compared with placebo after 24 weeks, and the safety (up to 52 weeks) of HSK7653 in Chinese patients with Type 2 diabetes who are insufficient…
- Trial name
- NCT04556851
- Testing
- HSK7653 10 mg Q2W, HSK7653 25 mg Q2W
- Where
- 2 sites in China
- Volunteers
- 476 people
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Type 2 Diabetes Mellitus
Welchol as Monotherapy for Type 2 Diabetes Mellitus
The current study investigates Welchol as monotherapy to improve glycemic control in subjects with Type 2 Diabetes Mellitus not adequately controlled with diet and exercise alone.
- Trial name
- NCT00789737
- Testing
- Welchol
- Where
- 107 sites in United States
- Volunteers
- 357 people
- Sponsor
- Daiichi Sankyo
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Singapore
This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control and complications in diabetic subjects in Asia.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare Asia (NCT00836030)
- Testing
- No treatment given
- Where
- Singapore
- Volunteers
- 854 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A New Oral Treatment For Type II Diabetes Mellitus
This is a 24-week study investigating the safety and efficacy of several dosages of a potential new oral medicine for Type II diabetes mellitus.
- Trial name
- NCT00111800
- Testing
- DEN 2.5 mg, DEN 7.5 mg, DEN 15 mg
- Where
- 109 sites in United States, Canada and 8 more
- Volunteers
- 375 people
- Sponsor
- GlaxoSmithKline
Diabetic Nephropathies, Diabetes Mellitus, Type 2
Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy
This is a proof of concept (PoC) trial to evaluate the safety, tolerability and renal effect of APX-115 in subjects with Type 2 diabetes and nephropathy.
- Conditions
- Diabetic Nephropathies, Diabetes Mellitus, Type 2, Nephropathy, Diabetic
- Trial name
- NCT04534439
- Testing
- APX-115
- Where
- 16 sites in Bulgaria, Czechia and 2 more
- Volunteers
- 140 people
- Sponsor
- Aptabio Therapeutics, Inc.
Diabetes, Diabetes Mellitus, Type 2
Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes
This study is conducted in Europe. The aim of the study was to evaluate the safety and efficacy of biphasic insulin aspart 30 (NovoMix® 30) when switching to a modern premix insulin analogue treatment compared to previous insulin…
- Trial name
- NCT01536639
- Testing
- biphasic insulin aspart 30
- Where
- Slovakia
- Volunteers
- 454 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Safety and Efficacy of Autologous Adipose-Derived Stem Cell Transplantation in Type 2 Diabetics
The purpose of this study is to determine whether intravenous administration of autologous adipose-derived stem cells is of benefit in the management of types 2 diabetics.
- Trial name
- NCT00703612
- Testing
- Autologous Adipose-derived Stem cells
- Where
- 2 sites in Philippines
- Volunteers
- 34 people
- Sponsor
- Adistem Ltd